Royalty Report: Drugs, Personal Care Products, Therapeutic – Collection: 1593


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Personal Care Products
  • Therapeutic
  • Healthcare
  • Disease
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 1593

License Grant
The Company entered into an exclusive agreement for worldwide representation, manufacturing, marketing and distribution rights to a zinc gluconate/glycine lozenge formulation developed by Licensor and patented in the United States, United Kingdom, Sweden, France, Italy, Canada, Germany, and pending in Japan.
License Property
The Cold-Eeze(R) lozenge products are based upon a proprietary zinc gluconate formula which in a clinical study conducted by The Cleveland Clinic has been shown to reduce the severity and duration of the common cold symptoms.

Patent for the use of zinc gluconate to reduce the duration of the common cold (Patent RE 33,465). Licensor is the owner of certain patents for flavoring for zinc supplements for oral use (Patent 4,684,528 and 4,758,439)

IPSCIO Record ID: 167340

License Grant
This agreement is to provide Licensee  with sole and exclusive rights to make, use, and sell various  products, including lozenges, under The Patent by license granted by Licensor.
License Property
The trademarks include 'Cold-Eeze' and 'Cold-Eezer Plus', containing zinc gluconate under license granted.

Cold-Eeze(TM) product is a homeopathic remedy which is subject to regulation by various federal, state and local agencies, including the FDA and the Homeopathic Pharmacopoeia of the United States.

4,503,070  Method for reducing the duration of the common cold
4,684,528  Flavor of zinc supplements for oral use

Field of Use
Cold-Eeze(TM) is a patented cold relief lozenge product.

IPSCIO Record ID: 5951

License Grant
The Licensee entered into a certain license agreement with Licensor, an individual, for a worldwide, sub-licensable right to make, use and sell Licensor's proprietary products, technology and patents relating to the treatment of the common cold with zinc.  The Licensee obtained an exclusive license relating to the treatment of the common cold with a patented formula of zinc acetate.
Field of Use
The Licensee intends to introduce the Zinc Product during 2007 in prescription and over-the-counter combinations under the tradename Zinx, as a stand-alone product, Zinx is an over-the-counter, or self-medication, homeopathic zinc lozenge based on a patented zinc acetate formulation. The four-gram peppermint flavored Zinx lozenge releases 14.0 mg zinc ions. It is targeted at the cough and cold market category and is generally indicated for prevention of and relief of the common cold.

IPSCIO Record ID: 5269

License Grant
The Companies today announced a settlement of the patent infringement lawsuit that was filed in 1999 on Zicam Cold Remedy.
License Property
Zicam Cold Remedy has become one of the top-selling cold remedies in the country over the past two years and has been clinically proven to reduce the duration of the common cold by an average of 75% when taken at the onset of symptoms.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.